148 related articles for article (PubMed ID: 18500268)
1. Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus.
Scheil-Bertram S; Lorenz D; Ell C; Sheremet E; Fisseler-Eckhoff A
Mod Pathol; 2008 Aug; 21(8):961-7. PubMed ID: 18500268
[TBL] [Abstract][Full Text] [Related]
2. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Dorer R; Odze RD
Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330
[TBL] [Abstract][Full Text] [Related]
3. Value of α-methylacyl-CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus.
Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
Histopathology; 2013 Nov; 63(5):630-9. PubMed ID: 24004067
[TBL] [Abstract][Full Text] [Related]
4. A study of indefinite for dysplasia in Barrett's oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (alpha-methylacyl-CoA-racemase).
Sonwalkar SA; Rotimi O; Scott N; Verghese E; Dixon M; Axon AT; Everett SM
Histopathology; 2010 Jun; 56(7):900-7. PubMed ID: 20636793
[TBL] [Abstract][Full Text] [Related]
5. Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium.
Lisovsky M; Falkowski O; Bhuiya T
Hum Pathol; 2006 Dec; 37(12):1601-6. PubMed ID: 16996568
[TBL] [Abstract][Full Text] [Related]
6. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma.
Lagorce C; Paraf F; Vidaud D; Couvelard A; Wendum D; Martin A; Fléjou JF
Histopathology; 2003 May; 42(5):457-65. PubMed ID: 12713622
[TBL] [Abstract][Full Text] [Related]
8. Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach.
Lee WA
Oncology; 2006; 71(3-4):246-50. PubMed ID: 17652945
[TBL] [Abstract][Full Text] [Related]
9. p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus.
Shi XY; Bhagwandeen B; Leong AS
Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):447-52. PubMed ID: 18665038
[TBL] [Abstract][Full Text] [Related]
10. a-Methylacyl coenzyme A racemase is highly expressed in the intestinal-type adenocarcinoma and high-grade dysplasia lesions of the stomach.
Huang W; Zhao J; Li L; Huang Y; Yang X; Wang J; Zhang T
Histol Histopathol; 2008 Nov; 23(11):1315-20. PubMed ID: 18785113
[TBL] [Abstract][Full Text] [Related]
11. Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression.
Brun R; Naroditsky I; Waterman M; Ben-Izhak O; Groisman G; Ilan N; Vlodavsky I
Mod Pathol; 2009 Dec; 22(12):1548-54. PubMed ID: 19749739
[TBL] [Abstract][Full Text] [Related]
12. A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
Ahmad J; Arthur K; Maxwell P; Kennedy A; Johnston BT; Murray L; McManus DT
Dis Esophagus; 2015 Apr; 28(3):276-82. PubMed ID: 24612412
[TBL] [Abstract][Full Text] [Related]
13. Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus.
Lagorce-Pagès C; Paraf F; Wendum D; Martin A; Fléjou JF
Virchows Arch; 2004 May; 444(5):426-35. PubMed ID: 15045585
[TBL] [Abstract][Full Text] [Related]
14. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
[TBL] [Abstract][Full Text] [Related]
15. IMP3 Immunoreactivity is More Sensitive Than AMACR in Detecting Dysplastic Epithelium and Early Adenocarcinoma in Barrett Esophagus.
Gadara MR; Gonzalez M; Cartun RW; Ligato S
Appl Immunohistochem Mol Morphol; 2017 Jul; 25(6):386-391. PubMed ID: 26766126
[TBL] [Abstract][Full Text] [Related]
16. A comparative cytopathologic and histologic study of atypia, dysplasia, and adenocarcinoma in Barrett's esophagus.
Geisinger KR; Teot LA; Richter JE
Cancer; 1992 Jan; 69(1):8-16. PubMed ID: 1727677
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Morris CD; Armstrong GR; Bigley G; Green H; Attwood SE
Am J Gastroenterol; 2001 Apr; 96(4):990-6. PubMed ID: 11316217
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
[TBL] [Abstract][Full Text] [Related]
19. Dysplasia in Random Biopsies from Barrett's Surveillance Is an Important Marker for More Severe Pathology.
Noordzij IC; Van Loon van de Ende MCM; Curvers WL; van Lijnschoten G; Huysentruyt CJ; Schoon EJ
Dig Dis Sci; 2021 Jun; 66(6):1957-1964. PubMed ID: 32661766
[TBL] [Abstract][Full Text] [Related]
20. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma.
Morales CP; Lee EL; Shay JW
Cancer; 1998 Aug; 83(4):652-9. PubMed ID: 9708927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
